In Vitro Diagnostics Technology and Industry Development Summit
June 18-20, 2011
Shanghai Everbright Convention & Exhibition Center, China
Identify the key trends and developments that are driving the In Vitro Diagnostics market in China and globally;
Learn about the latest technical developments of pharma and diagnostics through presentations and panel discussions;
Analyze the most viable In Vitro diagnostics sectors to successfully align your future strategies;
Examine regulatory challenges and how they can be overcome.
Further details for scientific sessions are outlined at Agenda.
Attendees include: Clinicians, Laboratory Developers, Chief Executives, Vice Presidents, Directors, Chief Scientists, Project Leaders of Molecular Genetics, Molecular Medicine, Molecular Diagnostics and other related areas who develop, provide, and perform IVD solutions.
Organized by eChinaChem, Inc., Shanghai Licensed Pharmacist Association, The Shanghai Medical Instrument Trade Association, Research Center of Econometrics, Shanghai Academy of Social Sciences, In Vitro Diagnostics Technology and Industry Development Summit every year since 2011. For more information about the organizers, please refer to Organizers.
IVD development is at the frontier of medical services and research, and is a key area in preventive medicine R&D. Innovations and advancement in various IVD technologies have led to the development of new diagnostics test applications, resulting in a phenomenal growth of the IVD market. The IVD market of China, averaging double-digit growth annually in the past decade, has fostered competition amongst IVD firms in recent years, thus accelerating development of new technologies and products.
The global IVD market totaled $34 billion in 2007 and $38 billion for 2008. Despite the 2009 global economic crisis, the conditions of the traditional IVD market has not changed and it is expected to generate an annualized 9% growth rate from 2010 to 2012 according to market analysts.
At present, China is still one of the lowest IVD consumption per capita countries, with about 1/5 of the population of the world and only 2% of the global IVD industry market share. Yet China is the fastest growing market, with an average annual growth rate of 15%.
The 2009 outbreak of Influenza A (H1N1) has stimulated the IVD industry. Many pharmaceutical companies utilized IVD detection kits for influenza virus research and development investment, and benefited from related IVD R&D efforts.
This Summit will discuss commercial and regulatory challenges in China, the recent development of diagnostic reagents in the biopharmaceutical industry, emerging technologies in diagnostics and other development for IVD, and will offer an opportunity for persons interested in every aspect of IVD to become familiar with cutting-edge developments and their potential application in IVD arenas.
Sessions during the conference will include
Session 1: In Vitro Diagnostics: Commercial and Regulatory Challenges in China
Session 2: Recent Development of Diagnostic Reagents in Biopharmaceutical Industry
Session 3: Clinical Applications of Molecular Diagnostics
Session 4: Molecular Diagnostics and Personalized Medicine
Session 5: Emerging Technologies in Diagnostics
Session 6: High-throughput，Rapid and Low cost Detection Technologies
Session 7: Biomarkers in Diagnostics
Session 8: Proteomics, Pharmacogenomics and Companion Diagnostics
Session 9: Point-of-Care Diagnostic Systems
Session 10: Biochips and Biosensors based Molecular Diagnostics
Session 11: Total solution of Molecular Diagnostics: From sample to results
Session 12: Diagnostic Reagents: From Bench to Bedside
Session 13: Prenatal Diagnosis
Session 14: Infectious Disease and Rapid Detection
Session 15: Cancer Prevention and Early Detection
Session 16: Diagnostic Reagents for Genetic Disease
Session 17: Cardiovascular Diagnostics
Session 18: Diabetes and Other Metabolic Disease
Ms. Sophia Huang
3/F, Bldg 1,Hengchen Plaza, 338 Tianshan Road
Shanghai, 200336 China
Tel: +86 (21) 5169 1611 Ext 1087
Fax: +86 (21) 5240 1255